Product Information

Omilancor (BT-11) is an orally active LANCL2-binding compound for treating inflammatory bowel disease with a Kd value of 7.7 µM.

CAS No.	1912399-75-7
Product Name	Omilancor

Heavy Atom Count	40	Rotatable Bond Count	4
Atom Stereo Count	0	Bond Stereo Count	0
HBA	6	HBD	2
TPSA	123.760 Å²	Charge	0
Exact Mass	528.20222	Complexity	1680.00
pKa	5.875	XLogP	4.161

Studies related to this compound and its mechanism of action

Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation.

Inflammatory bowel diseases • Vol. 30, Issue 1 • 2024

PMID: 37436905 DOI: 10.1093/ibd/izad124

Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease.

Inflammatory bowel diseases • Vol. 30, Issue 4 • 2024

PMID: 37934790 DOI: 10.1093/ibd/izad258

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020

PMID: 32020584 PMC: PMC7160657 DOI: 10.1111/imm.13175

The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.

Inflammatory bowel diseases • Vol. 26, Issue 4 • 2020

PMID: 31077582 DOI: 10.1093/ibd/izz094

Products
Product catalog
Browse all compounds
API & Candidates
Featured products
Membrane Protein Solubilization & Stabilization
Bioluminescence Imaging & Luciferase Assays
Density Gradient Medium for Cell Separation
Specialty Resins & Solid Supports
Nucleic Acid Synthesis & Conjugation Materials
GalNAc Ligands & Building Blocks
All featured products
Services
CDMO & Manufacturing
Custom Synthesis
Process Development
Lab To Pilot
Commercialization
Generic APIs
CRO
Preclinical
Pharmacology & Efficacy
DMPK & Bioanalysis
Toxicology & Safety
Disease Models
Technologies
High-Potent
Chiral Synthesis
Cloud Synthesis
Fermentation
Flow Chemistry
Biocatalysis
Support
Regulatory Support
Supply Chain Solutions
About
Perspectives
Contact

HomeHome
ProductsProducts
Materials ScienceMaterials Science
MOF LigandsMOF Ligands
Nitrogen containing MOF ligandsNitrogen containing MOF ligands
OmilancorOmilancor

Omilancor

CAS No.	1912399-75-7
MDL No.	N/A
MF	C₃₀H₂₄N₈O₂
MW	528.60
InChI Key	MVHWZNBAQIGPOQ-UHFFFAOYSA-N

CUSTOM SYNTHESIS

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Omilancor (BT-11) is an orally active LANCL2-binding compound for treating inflammatory bowel disease with a Kd value of 7.7 µM.

CAS No.	1912399-75-7
Product Name	Omilancor

Heavy Atom Count	40	Rotatable Bond Count	4
Atom Stereo Count	0	Bond Stereo Count	0
HBA	6	HBD	2
TPSA	123.760 Å²	Charge	0
Exact Mass	528.20222	Complexity	1680.00
pKa	5.875	XLogP	4.161

Studies related to this compound and its mechanism of action

Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation.

Inflammatory bowel diseases • Vol. 30, Issue 1 • 2024

PMID: 37436905 DOI: 10.1093/ibd/izad124

Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease.

Inflammatory bowel diseases • Vol. 30, Issue 4 • 2024

PMID: 37934790 DOI: 10.1093/ibd/izad258

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020

PMID: 32020584 PMC: PMC7160657 DOI: 10.1111/imm.13175

The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.

Inflammatory bowel diseases • Vol. 26, Issue 4 • 2020

PMID: 31077582 DOI: 10.1093/ibd/izz094

Your Partner for
Complex Chemistry

About Us
Perspectives
Products
Contact

Preclinical Development
Technologies
Custom Synthesis

Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT

Westerstraat 10, 3016 DH, Rotterdam, The Netherlands

EU US

Westerstraat 10, 3016 DH, Rotterdam, The Netherlands

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|

Omilancor

Pricing & Availability

Product Information

Properties

Omilancor

Pricing & Availability

Product Information

Properties

Documentation

Omilancor

Pricing & Availability

Product Information

Properties

Related Articles

Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation.

Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease.

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.

Omilancor

Pricing & Availability

Product Information

Properties

Related Articles

Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation.

Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease.

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.

Documentation